Suppr超能文献

共晶在生物相关介质中的溶解及其从药物溶解情况的预测

Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization.

作者信息

Lipert Maya P, Roy Lilly, Childs Scott L, Rodríguez-Hornedo Naír

机构信息

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109-1065.

Renovo Research, Atlanta, Georgia 30316.

出版信息

J Pharm Sci. 2015 Dec;104(12):4153-4163. doi: 10.1002/jps.24640. Epub 2015 Sep 21.

Abstract

This work examines cocrystal solubility in biorelevant media (FeSSIF, fed-state simulated intestinal fluid), and develops a theoretical framework that allows for the simple and quantitative prediction of cocrystal solubilization from drug solubilization. The solubilities of four hydrophobic drugs and seven cocrystals containing these drugs were measured in FeSSIF and in acetate buffer at pH 5.00. In all cases, the cocrystal solubility (Scocrystal ) was higher than the drug solubility (Sdrug ) in both buffer and FeSSIF; however, the solubilization ratio of drug, SRdrug = (SFeSSIF /Sbuffer )drug , was not the same as the solubilization ratio of cocrystal, SRcocrystal = (SFeSSIF /Sbuffer )cocrystal , meaning drug and cocrystal were not solubilized to the same extent in FeSSIF. This highlights the potential risk of anticipating cocrystal behavior in biorelevant media based on solubility studies in water. Predictions of SRcocrystal from simple equations based only on SRdrug were in excellent agreement with measured values. For 1:1 cocrystals, the cocrystal solubilization ratio (SR) can be obtained from the square root of the drug SR. For 2:1 cocrystals, SRcocrystal is found from (SRdrug )(2/3) . The findings in FeSSIF can be generalized to describe cocrystal behavior in other systems involving preferential solubilization of a drug such as surfactants, lipids, and other drug solubilizing media.

摘要

本研究考察了共晶在生物相关介质(FeSSIF,进食状态模拟肠液)中的溶解度,并建立了一个理论框架,可根据药物溶解度对共晶溶解进行简单定量预测。测定了四种疏水性药物以及包含这些药物的七种共晶在FeSSIF和pH 5.00的醋酸盐缓冲液中的溶解度。在所有情况下,共晶溶解度(Scocrystal)在缓冲液和FeSSIF中均高于药物溶解度(Sdrug);然而,药物的溶解比,SRdrug = (SFeSSIF /Sbuffer)drug,与共晶的溶解比,SRcocrystal = (SFeSSIF /Sbuffer)cocrystal,并不相同,这意味着药物和共晶在FeSSIF中的溶解程度不同。这突出了基于水中溶解度研究来预测共晶在生物相关介质中行为的潜在风险。仅基于SRdrug的简单方程对SRcocrystal的预测与测量值高度吻合。对于1:1共晶,共晶溶解比(SR)可从药物SR的平方根得出。对于2:1共晶,SRcocrystal可由(SRdrug)(2/3)得出。在FeSSIF中的研究结果可推广用于描述其他涉及药物优先溶解的体系(如表面活性剂、脂质和其他药物增溶介质)中共晶的行为。

相似文献

1
Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization.
J Pharm Sci. 2015 Dec;104(12):4153-4163. doi: 10.1002/jps.24640. Epub 2015 Sep 21.
2
Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents.
Mol Pharm. 2015 Oct 5;12(10):3535-46. doi: 10.1021/acs.molpharmaceut.5b00111. Epub 2015 Aug 28.
3
Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5.
Adv Drug Deliv Rev. 2016 Jun 1;101:143-166. doi: 10.1016/j.addr.2016.04.022. Epub 2016 Apr 29.
4
The role of pH and dose/solubility ratio on cocrystal dissolution, drug supersaturation and precipitation.
Eur J Pharm Sci. 2020 Sep 1;152:105422. doi: 10.1016/j.ejps.2020.105422. Epub 2020 Jun 10.
5
The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs.
Pharm Dev Technol. 2011 Jun;16(3):278-86. doi: 10.3109/10837451003664099. Epub 2010 Mar 10.
6
Engineering cocrystal solubility, stability, and pH(max) by micellar solubilization.
J Pharm Sci. 2011 Dec;100(12):5219-34. doi: 10.1002/jps.22725. Epub 2011 Sep 9.
7
A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies.
Eur J Pharm Biopharm. 2016 Oct;107:142-50. doi: 10.1016/j.ejpb.2016.07.006. Epub 2016 Jul 5.
8
Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities.
J Pharm Sci. 2018 Jan;107(1):113-120. doi: 10.1016/j.xphs.2017.10.033. Epub 2017 Oct 31.
9
pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media.
Mol Pharm. 2012 Sep 4;9(9):2605-12. doi: 10.1021/mp300189b. Epub 2012 Aug 23.
10
Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids.
Eur J Pharm Sci. 2011 Jul 17;43(4):260-9. doi: 10.1016/j.ejps.2011.04.016. Epub 2011 May 1.

引用本文的文献

1
Eutectic Formation of Naproxen with Some Dicarboxylic Acids.
Pharmaceutics. 2021 Dec 4;13(12):2081. doi: 10.3390/pharmaceutics13122081.
2
Obtaining Cocrystals by Reaction Crystallization Method: Pharmaceutical Applications.
Pharmaceutics. 2021 Jun 17;13(6):898. doi: 10.3390/pharmaceutics13060898.
3
Enhanced Dissolution of Naproxen by Combining Cocrystallization and Eutectic Formation.
Pharmaceutics. 2021 Apr 25;13(5):618. doi: 10.3390/pharmaceutics13050618.
4
Engineering Cocrystals of PoorlyWater-Soluble Drugs to Enhance Dissolution in Aqueous Medium.
Pharmaceutics. 2018 Jul 31;10(3):108. doi: 10.3390/pharmaceutics10030108.
6
Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5.
Adv Drug Deliv Rev. 2016 Jun 1;101:143-166. doi: 10.1016/j.addr.2016.04.022. Epub 2016 Apr 29.
7
How cocrystals of weakly basic drugs and acidic coformers might modulate solubility and stability.
Chem Commun (Camb). 2016 Apr 30;52(34):5832-5. doi: 10.1039/c6cc00898d. Epub 2016 Apr 4.

本文引用的文献

1
Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents.
Mol Pharm. 2015 Oct 5;12(10):3535-46. doi: 10.1021/acs.molpharmaceut.5b00111. Epub 2015 Aug 28.
2
pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media.
Mol Pharm. 2012 Sep 4;9(9):2605-12. doi: 10.1021/mp300189b. Epub 2012 Aug 23.
3
Engineering cocrystal solubility, stability, and pH(max) by micellar solubilization.
J Pharm Sci. 2011 Dec;100(12):5219-34. doi: 10.1002/jps.22725. Epub 2011 Sep 9.
4
Cocrystals of quercetin with improved solubility and oral bioavailability.
Mol Pharm. 2011 Oct 3;8(5):1867-76. doi: 10.1021/mp200209j. Epub 2011 Aug 25.
6
Bioavailability of indomethacin-saccharin cocrystals.
J Pharm Pharmacol. 2010 Nov;62(11):1560-8. doi: 10.1111/j.2042-7158.2010.01189.x.
7
The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs.
Pharm Dev Technol. 2011 Jun;16(3):278-86. doi: 10.3109/10837451003664099. Epub 2010 Mar 10.
9
Performance comparison of a co-crystal of carbamazepine with marketed product.
Eur J Pharm Biopharm. 2007 Aug;67(1):112-9. doi: 10.1016/j.ejpb.2006.12.016. Epub 2006 Dec 28.
10
Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
Pharm Res. 2006 Aug;23(8):1888-97. doi: 10.1007/s11095-006-9032-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验